🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. Toripalimab + Chemotherapy

    Coherus Oncology

    Head and Neck Cancer

    phase 2 small molecule active

    1 trial

  2. TransCon TLR7/8 Agonist, TransCon IL-2 ß/ү, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Lacuna Pharma Pty Ltd

    Locally advanced or metastatic solid tumor malignancies, platinum resistant ovarian cancer, post-anti-pd-1 melanoma, second line or later cervical cancer, neoadjuvant melanoma and neoadjuvant non-small cell lung cancer, post-anti-pd-L1 non-small cell lung cancer, post-anti-pd-L1 small cell lung cancer, second line or later HER2+ breast cancer

    phase 2 small molecule active

    1 trial

  3. Transarterial chemoembolization

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Unresectable Colorectal Cancer

    phase 2 other active

    1 trial

  4. Trastuzumab

    KAZIA THERAPEUTICS LTD

    Breast Cancer

    phase 2 small molecule terminated

    1 trial

  5. Trastuzumab

    PUMA BIOTECHNOLOGY, INC.

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  6. Trastuzumab in Combination with TS-ONE and cisplatin

    Hospital Authority, Hong Kong

    Gastric Cancer

    phase 2 small molecule active

    1 trial

  7. Trilaciclib

    The First People's Hospital of Lianyungang

    Advanced Squamous Non-Small-Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  8. Trilaciclib and Sacituzumab Tirumotecan

    The First People's Hospital of Lianyungang

    NSCLC (Advanced Non-small Cell Lung Cancer)

    phase 2 small molecule active

    1 trial

  9. Trodelvy 200 mg powder for concentrate for solution for infusion, Carboplatin 10 mg/ml Concentrate for Solution for Infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Gilead Sciences Pty Limited

    Non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  10. Tumor Intiltrating Lymphocytes (TIL) – VHIO, Fludarabina Teva 25 mg/ml concentrado para solución para perfusión o inyección EFG, Melanoma Tumor Intiltrating Lymphocytes (TIL) – NKI, Fludarabine - PCH 25 mg/ml, concentraat voor oplossing voor intraveneuze infusie of injectie, ANV419, Fludarabinphosphat "Ebewe", koncentrat til injektions-/infusionsvæske, opløsning, Genoxal 1.000 mg polvo para solución inyectable y para perfusión, PROLEUKIN, 18x106 UI polvo para solución inyectable o para perfusión, PROLEUKIN®

    The George Institute

    Advanced selected solid tumors: melanoma, non-small cell lung cancer (NSCLC) and cervical cancer.

    phase 2 small molecule active

    1 trial

  11. Tumor infiltrating lymphocytes (TIL) LN-145

    Iovance Biotherapeutics B.V.

    Metastatic Triple Negative Breast Cancer

    phase 2 small molecule completed

    1 trial

  12. Tumour heterogeneity studies based on dedicated breast PET using proliferation radiotracers: early detection of the treatment response.

    The George Institute

    Breast cancer

    phase 2 other active

    1 trial

  13. US-guided RFA

    The First People's Hospital of Lianyungang

    Liver Cancer

    phase 2 other active

    1 trial

  14. Ubamatamab

    Regeneron UK Limited

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  15. Ubamatamab

    Regeneron UK Limited

    Advanced/Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  16. Ubamatamab

    Regeneron UK Limited

    Recurrent Ovarian Cancer

    phase 2 small molecule active

    1 trial

  17. Ubamatamab, TOCILIZUMAB, Ubamatamab, Kevzara 175 mg/ml solution for injection, CEMIPLIMAB, LIBTAYO 350 mg concentrate for solution for infusion., Sarilumab

    Lacuna Pharma Pty Ltd

    Fallopian Tube Cancer, Endometrial Cancer, Ovarian Cancer, Primary Peritoneal Cancer

    phase 2 small molecule active

    1 trial

  18. Utidelone

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer

    phase 2 small molecule active

    1 trial

  19. VATS

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 other active

    1 trial

  20. VESANOID 10 mg, capsule molle

    The George Institute

    Oligometastatic solid cancer

    phase 2 small molecule active

    1 trial

  21. VIR-5818

    Vir Biotechnology

    Locally Advanced or Metastatic HER2-Expressing Cancers

    phase 2 small molecule active

    1 trial

  22. VS-6766, VS-6063

    Vera Therapeutics

    Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

    phase 2 small molecule active

    1 trial

  23. Vaccine

    Atrium Therapeutics

    Pediatric Cancer

    phase 2 mab active

    1 trial

  24. Valemetostat Tosylate, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Valemetostat Tosylate

    Daiichi Sankyo

    Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources